Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Functional imaging of legumain in cancer using a new quenched activity-based probe.

Edgington LE, Verdoes M, Ortega A, Withana NP, Lee J, Syed S, Bachmann MH, Blum G, Bogyo M.

J Am Chem Soc. 2013 Jan 9;135(1):174-82. doi: 10.1021/ja307083b. Epub 2012 Dec 18.

2.

Legumain is activated in macrophages during pancreatitis.

Edgington-Mitchell LE, Wartmann T, Fleming AK, Gocheva V, van der Linden WA, Withana NP, Verdoes M, Aurelio L, Edgington-Mitchell D, Lieu T, Parker BS, Graham B, Reinheckel T, Furness JB, Joyce JA, Storz P, Halangk W, Bogyo M, Bunnett NW.

Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G548-60. doi: 10.1152/ajpgi.00047.2016. Epub 2016 Aug 11.

PMID:
27514475
3.

Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection.

Chen YJ, Wu SC, Chen CY, Tzou SC, Cheng TL, Huang YF, Yuan SS, Wang YM.

Biomaterials. 2014 Jan;35(1):304-15. doi: 10.1016/j.biomaterials.2013.09.100. Epub 2013 Oct 10.

PMID:
24120038
4.
5.

Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain.

Lee J, Bogyo M.

Bioorg Med Chem Lett. 2012 Feb 1;22(3):1340-3. doi: 10.1016/j.bmcl.2011.12.079. Epub 2011 Dec 21.

6.

Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain.

Sexton KB, Witte MD, Blum G, Bogyo M.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):649-53. Epub 2006 Nov 6.

7.

Legumain expression, activity and secretion are increased during monocyte-to-macrophage differentiation and inhibited by atorvastatin.

Solberg R, Smith R, Almlöf M, Tewolde E, Nilsen H, Johansen HT.

Biol Chem. 2015 Jan;396(1):71-80. doi: 10.1515/hsz-2014-0172.

PMID:
25205715
8.

Molecular-dynamics-simulation-driven design of a protease-responsive probe for in-vivo tumor imaging.

Jiang Y, Lu J, Wang Y, Zeng F, Wang H, Peng H, Huang M, Jiang H, Luo C, Huang Y.

Adv Mater. 2014 Dec 23;26(48):8174-8. doi: 10.1002/adma.201403547. Epub 2014 Oct 22.

PMID:
25338710
9.

Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis.

Clerin V, Shih HH, Deng N, Hebert G, Resmini C, Shields KM, Feldman JL, Winkler A, Albert L, Maganti V, Wong A, Paulsen JE, Keith JC Jr, Vlasuk GP, Pittman DD.

Atherosclerosis. 2008 Nov;201(1):53-66. doi: 10.1016/j.atherosclerosis.2008.01.016. Epub 2008 Feb 21.

PMID:
18377911
10.

Nuclear legumain activity in colorectal cancer.

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM.

PLoS One. 2013;8(1):e52980. doi: 10.1371/journal.pone.0052980. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/05c95441-890f-4707-a1bc-c4d386561191.

11.

Enhancement of DNA vaccine potency against legumain.

Smahel M, Duskova M, Polakova I, Musil J.

J Immunother. 2014 Jun;37(5):293-303. doi: 10.1097/CJI.0000000000000040.

PMID:
24810641
12.

Cy5-labeled aza-peptidyl Pro-Asn epoxide.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 May 12 [updated 2010 Jun 3].

13.

Dynamic imaging of protease activity with fluorescently quenched activity-based probes.

Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, Sloane BF, Bogyo M.

Nat Chem Biol. 2005 Sep;1(4):203-9. Epub 2005 Aug 14.

PMID:
16408036
14.

Expression and protease activity of mouse legumain are regulated by the oncogene/transcription co-activator, DJ-1 through p53 and cleavage of annexin A2 is increased in DJ-1-knockout cells.

Yamane T, Yamamoto Y, Nakano Y, Nakagaki T, Ohkubo I, Ariga H.

Biochem Biophys Res Commun. 2015 Nov 20;467(3):472-7. doi: 10.1016/j.bbrc.2015.10.032. Epub 2015 Oct 14.

PMID:
26462467
15.

A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.

Stern L, Perry R, Ofek P, Many A, Shabat D, Satchi-Fainaro R.

Bioconjug Chem. 2009 Mar 18;20(3):500-10. doi: 10.1021/bc800448u.

PMID:
19196156
16.

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.

Lewēn S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, Xiang R, Luo Y.

Cancer Immunol Immunother. 2008 Apr;57(4):507-15. Epub 2007 Sep 5.

PMID:
17786443
17.
18.

High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K.

Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11.

PMID:
25466510
19.

In vivo imaging of tumors with protease-activated near-infrared fluorescent probes.

Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr.

Nat Biotechnol. 1999 Apr;17(4):375-8.

PMID:
10207887
20.

Proteinases participating in the processing and activation of prolegumain in primary cultured rat macrophages.

Lecaille F, Muno D, Kominami E, Ishidoh K.

Biol Chem. 2004 Jun;385(6):511-6.

PMID:
15255183

Supplemental Content

Support Center